Brianna Hoffner Discusses Complex Immune-Related Adverse Events

Video

Brianna Hoffner, MSN, NP, RN, discusses complex immune-related adverse events and how nurses can go about treating patients.

At the 2016 SITC Annual Meeting, Brianna Hoffner, MSN, NP, RN, from the University of Colorado Cancer Center discusses complex immune-related adverse events and the considerations that should go in to treating them.

In the example Hoffner uses, the cause of the patient’s symptoms must be parsed out, to discover which are the result of the immunotherapy agents. In this case, further diagnostic imaging provided the answer—that the patient was experiencing both pneumonitis and colitis concurrently.

Related Videos
Related Content
kidney cancer

Atezolizumab Falls Short in Pretreated, Advanced Renal Cell Carcinoma

June 17th 2023
Article

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Ask The Right Questions: Clinical Pearls of AE Management

Ask The Right Questions: Clinical Pearls of AE Management

February 15th 2022
Podcast

In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

June 3rd 2023
Article

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

Immunotherapy in the Age of COVID-19

Immunotherapy in the Age of COVID-19

August 15th 2020
Podcast

melanoma

mRNA Vaccine, Plus Pembrolizumab, Minimizes Recurrence Rate in Melanoma

April 22nd 2023
Article

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.

biliary tract cancer

Pembrolizumab in Addition to Cisplatin and Gemcitabine Boosts Overall Survival in Advanced Biliary Tract Cancer

April 20th 2023
Article

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

© 2024 MJH Life Sciences

All rights reserved.